K
Katharina Habenicht
Researcher at University of Erlangen-Nuremberg
Publications - 9
Citations - 281
Katharina Habenicht is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Immunology & Medicine. The author has an hindex of 4, co-authored 4 publications receiving 45 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself.
Marta Ferreira-Gomes,Andrey Kruglov,Andrey Kruglov,Pawel Durek,Frederik Heinrich,Caroline Tizian,Gitta Anne Heinz,Anna Pascual-Reguant,Weijie Du,Ronja Mothes,Chaofan Fan,Stefan Frischbutter,Katharina Habenicht,Lisa Budzinski,Justus Ninnemann,Péter K. Jani,Gabriela Maria Guerra,Katrin Lehmann,Mareen Matz,Lennard Ostendorf,Lukas Heiberger,Hyun-Dong Chang,Sandy Bauherr,Marcus Maurer,Günther Schönrich,Martin Raftery,Tilmann Kallinich,Marcus A. Mall,Stefan Angermair,Sascha Treskatsch,Thomas Dörner,Victor M. Corman,Andreas Diefenbach,Hans-Dieter Volk,Hans-Dieter Volk,Sefer Elezkurtaj,Thomas Winkler,Jun Dong,Anja E. Hauser,Helena Radbruch,Mario Witkowski,Fritz Melchers,Andreas Radbruch,Mir-Farzin Mashreghi +43 more
TL;DR: In this article, a single cell level analysis of plasmablasts egressed into the blood to study the dynamics of adaptive immune response in COVID-19 patients requiring intensive care.
Journal ArticleDOI
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Andreas Mackensen,Fabian Müller,Dimitrios Mougiakakos,Sebastian Böltz,Artur Wilhelm,Michael Aigner,Simon Völkl,David Simon,Arnd Kleyer,Luis E. Muñoz,Sascha Kretschmann,S. Kharboutli,Regina Gary,H. Reimann,Wolf Rösler,Stefan Uderhardt,Holger Bang,Martin Herrmann,Arif B. Ekici,Christian Buettner,Katharina Habenicht,Thomas Winkler,Gerhard Krönke,Georg Schett +23 more
TL;DR: Results from a study of five patients with refractory systemic lupus erythematosus, who were treated with anti-CD19 CAR T cell therapy under a compassionate-use program, demonstrate remission of SLE disease with follow-up of up to 17 months, suggesting that CD19CAR T cell transfer is feasible, tolerable and highly effective in SLE.
Journal ArticleDOI
Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
Pascal Irrgang,Juliane Gerling,Katharina Kocher,Dennis Lapuente,Philipp Steininger,Katharina Habenicht,Monika Wytopil,Stephanie Beileke,Simon T. Schäfer,Jahn Zhong,George Ssebyatika,Thomas Krey,Valeria Falcone,Christine Schülein,Antonia Sophia Peter,Krystelle Nganou-Makamdop,Hartmut Hengel,Jürgen Held,Christian Bogdan,Klaus Überla,Kilian Schober,Thomas Winkler,Matthias Tenbusch +22 more
TL;DR: In this article , the authors reported that after the initial two mRNA vaccine doses, the immunoglobulin G (IgG) response mainly consists of the proinflammatory subclasses IgG1 and IgG3.
Journal ArticleDOI
A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model
Antonia Sophia Peter,Edith Roth,Sebastian R. Schulz,Kirsten Fraedrich,Tobit Steinmetz,Dominik Damm,Manuela Hauke,Elie Richel,Sandra Mueller-Schmucker,Katharina Habenicht,Valentina Eberlein,Leila Issmail,Nadja Uhlig,Simon Dolles,Eva Grüner,David Peterhoff,David Peterhoff,Sandra Ciesek,Sandra Ciesek,Markus Hoffmann,Markus Hoffmann,Stefan Pöhlmann,Stefan Pöhlmann,Paul F. McKay,Robin J. Shattock,Roman Wölfel,Eileen Socher,Ralf Wagner,Jutta Eichler,Heinrich Sticht,Wolfgang Schuh,Frank Neipel,Armin Ensser,Dirk Mielenz,Matthias Tenbusch,Thomas Winkler,Thomas Grunwald,Klaus Überla,Hans-Martin Jäck +38 more
TL;DR: In this article, the SARS-CoV-2 spike protein was immunized with DNA encoding the spike protein of SARS and boosted with spike protein, and the authors identified 29 hybridoma antibodies that reacted with SARS spike protein.
Posted ContentDOI
In severe COVID-19, SARS-CoV-2 induces a chronic, TGF-β-dominated adaptive immune response
Marta Ferreira-Gomes,Andrey Kruglov,Pawel Durek,Frederik Heinrich,Caroline Tizian,Anne Heinz G,Pascual-Reguant A,Du W,Ronja Mothes,Fan C,Stefan Frischbutter,Katharina Habenicht,Lisa Budzinski,Justus Ninnemann,Péter K. Jani,Gabriela Maria Guerra,Katrin Lehmann,Mareen Matz,Lennard Ostendorf,Lukas Heiberger,H.-D. Chang,Sandy Bauherr,Marcus Maurer,Günther Schönrich,Martin Raftery,Tilmann Kallinich,Alexander Mall M,Stefan Angermair,Sascha Treskatsch,Thomas Dörner,Max Corman,Andreas Diefenbach,Hans-Dieter Volk,Sefer Elezkurtaj,Thomas Winkler,Dong J,Erika Hauser A,Helena Radbruch,Mario Witkowski,Fritz Melchers,Andreas Radbruch,Mir-Farzin Mashreghi +41 more
TL;DR: In severely affected COVID-19 patients SARS-CoV-2 triggers chronic immune reactions which are controlled by TGF-{beta}, with most of the activated B cells being no longer specific for the Sars-Cov-2 spike protein and its receptor binding domain, nor for nucleoprotein.